US-Ireland Research and Development Partnership Programme
The US-Ireland Research and Development Partnership Programme is run jointly by funding agencies across three jurisdictions: United States of America, Republic of Ireland and Northern Ireland. The Programme aims to increase the level of collaborative R&D among researchers and industry professionals across the three jurisdictions. It covers the full remit of the National Institutes of Health (NIH).
Scheme at a glance
|Funding available||Up to €700,000 direct costs per award for the Republic of Ireland partner, with additional funding for the United States of America and Northern Ireland partners|
|Duration of funding||12–60 months|
- Details of this award
The Partnership Programme collaboration aims to generate discoveries and innovations which:
• Are transferable to the marketplace, or
• Will lead to enhancements in health, disease prevention and healthcare.
Joint ‘tri-partite’ applications must be made by a team of US, Republic of Ireland and Northern Ireland researchers. Each funding agency will fund only the elements of the research that are undertaken in that particular agency’s jurisdiction. Partnership Programme funding must add significant value in excess of what would be achievable by the applicant if they were working alone, supported only by existing national funding.
The funding agencies for health-related applications include:
• In the US, the partner agency is the National Institutes of Health (NIH). The NIH comprises multiple agencies which offer a number of calls for proposals.
• In the Republic of Ireland (ROI), the partner agencies are Science Foundation Ireland (SFI) and the Health Research Board (HRB). They will co-fund the ROI component of any successful US-Ireland Research and Development Partnership Programme project on a 50:50 basis.
• In Northern Ireland (NI), the partner agency is the Health & Social Care R&D Division (HSC R&D Division).
- Who can apply?
A US-Ireland Research and Development Partnership Programme application must have a minimum of one applicant from each of the three jurisdictions. Significant participation by researchers in all three jurisdictions must be demonstrated in the application.
Researchers should be at mid-stage or senior stage in their career.
- How to apply
The applicant from each jurisdiction must submit an “Intention to Submit form” to the relevant funding agency at least 10 weeks in advance of the deadline for the full proposal at NIH. For all ROI-based applicants, this process will be managed by the SFI, which will consult with HRB as appropriate. For further details, please refer to Section 3 of the “Guidance for ROI and NI applicants for Submission of Tri‐partite Proposals to the National Institutes of Health (NIH)”.Close
The applicants from each jurisdiction will write a joint ‘tri-partite’ proposal in the RO1 format required by NIH. An almost final draft of this tri-partite proposal must be submitted to SFI and HRB for review at least six weeks before the relevant NIH deadline. For details of this procedure, please refer to Section 11 of the “Guidance for ROI and NI applicants for Submission of Tri-partite Proposals to the National Institutes of Health (NIH)”.
It is the responsibility of the US applicant to submit the tri-partite proposal to the NIH for review.
The application must have been reviewed and approved by the signatory approver at the research office (or equivalent) in the host institution before it is submitted to SFI. Therefore, applicants should ensure that they give the signatory approver sufficient time before the scheme closing date to review the application and approve it. Please note that many host institutions specify internal deadlines for this procedure.
- Apply for this award
- Contact us
- NIH Deadlines